免疫相关基因多态性对向乳腺癌细胞的trastuzumabin vitro的影响
Linyu Yu1,2,3,4, Congmin Zhang1,2,3, Liangyu Liu5
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Pharmacogenomics
|October 11, 2024
概括
免疫细胞中的遗传变异会影响乳腺癌的治疗. 一种特定的CD247基因多态性 (rs16859030) 在体外增强了特斯图祖马布介导的细胞毒性.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
背景情况:
- 特拉斯图祖马布是针对HER2阳性乳腺癌的向治疗.
- 个体对trastuzumab的反应有所不同,这表明存在遗传因素.
- 周围血液单核细胞 (PBMCs) 在对癌症治疗的免疫反应中发挥作用.
研究的目的:
- 探索免疫相关基因的遗传变异与trastuzumab的有效性之间的联系.
- 评估这些遗传差异如何影响PBMC介导的细胞毒性对乳腺癌细胞在体外.
主要方法:
- 分析了148名健康捐赠者和13名乳腺癌 (BC) 患者的PBMCs的托斯图祖马布中介细胞毒性,使用流细胞计.
- 在7个与免疫相关的基因中用Sequenom质量阵列对16个单核酸多态 (SNPs) 进行基因定型.
- 在不同基因型和治疗条件之间比较细胞毒性水平.
主要成果:
- 与基线水平相比,trastuzumab治疗显著增加了PBMC细胞毒性.
- 在个体中观察到trastuzumab诱导的细胞毒性的相当大的变异性.
- 具有CD247 rs16859030的T基因型的个体表现出比具有CC基因型的个体更高的细胞毒性.
结论:
- 在体外,CD247 rs16859030多态性与改变的trastuzumab介导的细胞毒性有关.
- 这一发现表明CD247基因在预测对trastuzumab的治疗反应方面可能发挥作用.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
1.9K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K